Molecular Formula | C18H22ClF3N6O2 |
Molar Mass | 446.8545 |
Solubility | 10 mM in DMSO |
Storage Condition | -20℃ |
Use | Introduction 5-[2,6-bis (4-morpholinyl)-4-pyrimidinyl]-4-(trifluoromethyl)-2-pyridinamide, also known as BKM120 (hydrochloride)(Buparlisib), is a new breast cancer drug developed by Novartis (Novartis). The treatment of metastatic breast cancer is currently in phase III clinical and confirmatory phase I/II clinical stage. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.238 ml | 11.189 ml | 22.379 ml |
5 mM | 0.448 ml | 2.238 ml | 4.476 ml |
10 mM | 0.224 ml | 1.119 ml | 2.238 ml |
5 mM | 0.045 ml | 0.224 ml | 0.448 ml |